Lupin Limited announced that it has received tentative approval from the United States Food and Drug Administration for its Abbreviated New Drug Application, Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, to market a generic equivalent of Juluca® Tablets, 50 mg/25 mg of ViiV Healthcare Company. Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca®) had estimated annual sales of USD 666 million in the U.S.